Esophageal Squamous Cell Carcinoma Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, "Esophageal Squamous Cell Carcinoma Pipeline Insights 2025" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Esophageal Squamous Cell Carcinoma pipeline landscape. It covers the Esophageal Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Esophageal Squamous Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Esophageal Squamous Cell Carcinoma Treatment Landscape. Click here to read more @ Esophageal Squamous Cell Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Esophageal Squamous Cell Carcinoma Pipeline Report

* In August 2025, Yuhan Corporation conducted a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can join the study. The purpose of this study is to find out whether a medicine called YH32364 helps people with locally advanced or metastatic cancers with EGFR overexpression.
* In July 2025, Daiichi Sankyo conducted a study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).
* In July 2025, Hoffmann-La Roche announced a study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).
* DelveInsight's Esophageal Squamous Cell Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Esophageal Squamous Cell Carcinoma treatment.
* The leading Esophageal Squamous Cell Carcinoma Companies such as BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc., and others.
* Promising Esophageal Squamous Cell Carcinoma Therapies such as Camrelizumab, SI-B001, Irinotecan, Paclitaxel, Cisplatin, JMT101 , and others.

Discover groundbreaking developments in Esophageal Squamous Cell Carcinoma therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Esophageal Squamous Cell Carcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Esophageal Squamous Cell Carcinoma Emerging Drugs Profile

* Tislelizumab: BeiGene

Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcR on macrophages. In pre-clinical studies, binding to FcR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene's immuno-oncology biologic program, and we believe it could serve as a key element of our immuno-oncology combination platform. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. Currently, it is in Phase III stage of clinical trial evaluation to treat Esophageal Squamous Cell Carcinoma.

* Serplulimab: Shanghai Henlius Biotech

Serplulimab (novel anti-PD-1 mAb) is the first innovative monoclonal antibody (mAb) developed by Henlius. Shanghai Henlius Biotech, announced that the phase 3 clinical study ASTRUM-007 of HANSIZHUANG (serplulimab) independently developed by the company in combination with chemotherapy as a first-line treatment for patients with locally advanced/metastatic esophageal squamous cell carcinoma (ESCC), met the co-primary endpoints of progression-free survival (PFS) and overall survival (OS) in a planned interim analysis, evaluated by the Independent Data Monitoring Committee (IDMC).

The Esophageal Squamous Cell Carcinoma Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Esophageal Squamous Cell Carcinoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Esophageal Squamous Cell Carcinoma Treatment.
* Esophageal Squamous Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Esophageal Squamous Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Esophageal Squamous Cell Carcinoma market.

Stay informed about the Esophageal Squamous Cell Carcinoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Esophageal Squamous Cell Carcinoma Unmet Needs [https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Esophageal Squamous Cell Carcinoma Companies

BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc. , and others.

Esophageal Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous

Esophageal Squamous Cell Carcinoma Products have been categorized under various Molecule types such as

* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine

Transform your understanding of the Esophageal Squamous Cell Carcinoma Pipeline! See the latest progress in drug development and clinical research @ Esophageal Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Esophageal Squamous Cell Carcinoma Pipeline Report

* Coverage- Global
* Esophageal Squamous Cell Carcinoma Companies- BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc., and others.
* Esophageal Squamous Cell Carcinoma Therapies- Camrelizumab, SI-B001, Irinotecan, Paclitaxel, Cisplatin, JMT101, and others.
* Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research-Access the Full Esophageal Squamous Cell Carcinoma Pipeline Analysis Today! @ Esophageal Squamous Cell Carcinoma Drugs and Companies [https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Introduction

2. Executive Summary

3. Esophageal Squamous Cell Carcinoma: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Esophageal Squamous Cell Carcinoma - DelveInsight's Analytical Perspective

7. Late Stage Products (Phase III)

8. Tislelizumab: BeiGene

9. Drug profiles in the detailed report.....

10. Mid Stage Products (Phase II)

11. RAPA-201: Rapa Therapeutics

12. Drug profiles in the detailed report.....

13. Early Stage Products (Phase I)

14. SGN-B6A: Seagen

15. Drug profiles in the detailed report.....

16. Preclinical and Discovery Stage Products

17. Drug name: Company name

18. Drug profiles in the detailed report.....

19. Inactive Products

20. Esophageal Squamous Cell Carcinoma Key Companies

21. Esophageal Squamous Cell Carcinoma Key Products

22. Esophageal Squamous Cell Carcinoma- Unmet Needs

23. Esophageal Squamous Cell Carcinoma- Market Drivers and Barriers

24. Esophageal Squamous Cell Carcinoma- Future Perspectives and Conclusion

25. Esophageal Squamous Cell Carcinoma Analyst Views

26. Esophageal Squamous Cell Carcinoma Key Companies

27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esophageal-squamous-cell-carcinoma-pipeline-outlook-report-2025-key-50-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/esophageal-squamous-cell-carcinoma-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.